These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. Zhang Y, Li JL, Fu Q, Wang XD, Liu LS, Wang CX, Xie W, Chen ZJ, Shu WY, Huang M. Acta Pharmacol Sin; 2013 Apr; 34(4):555-60. PubMed ID: 23503472 [Abstract] [Full Text] [Related]
3. Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis. Wang CE, Lu KP, Chang Z, Guo ML, Qiao HL. Gene; 2018 Jul 20; 664():44-49. PubMed ID: 29678659 [Abstract] [Full Text] [Related]
6. The Impact of ABCB1 SNPs on Tacrolimus Pharmacokinetics in Liver or Kidney Transplant Recipients: A Meta-analysis. Li Z, Wang X, Li D, Cheng S, Dong Y, Yang H, Li X. Curr Pharm Des; 2023 Jul 20; 29(29):2323-2335. PubMed ID: 37817654 [Abstract] [Full Text] [Related]
10. Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. Sharaki O, Zeid M, Moez P, Zakaria NH, Nassar E. Mol Biol Rep; 2015 Jan 15; 42(1):105-17. PubMed ID: 25240575 [Abstract] [Full Text] [Related]
11. Effect of ABCB1 3435C>T Genetic Polymorphism on Pharmacokinetic Variables of Tacrolimus in Adult Renal Transplant Recipients: A Systematic Review and Meta-analysis. Peng W, Lin Y, Zhang H, Meng K. Clin Ther; 2020 Oct 15; 42(10):2049-2065. PubMed ID: 32888708 [Abstract] [Full Text] [Related]
14. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Asano T, Takahashi KA, Fujioka M, Inoue S, Okamoto M, Sugioka N, Nishino H, Tanaka T, Hirota Y, Kubo T. Pharmacogenetics; 2003 Nov 15; 13(11):675-82. PubMed ID: 14583680 [Abstract] [Full Text] [Related]
15. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Bouamar R, Hesselink DA, van Schaik RH, Weimar W, Macphee IA, de Fijter JW, van Gelder T. Ther Drug Monit; 2011 Apr 15; 33(2):178-84. PubMed ID: 21383650 [Abstract] [Full Text] [Related]
16. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH. Clin Exp Pharmacol Physiol; 2006 Nov 15; 33(11):1093-8. PubMed ID: 17042920 [Abstract] [Full Text] [Related]
17. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China. Meng XG, Guo CX, Feng GQ, Zhao YC, Zhou BT, Han JL, Chen X, Shi Y, Shi HY, Yin JY, Peng XD, Pei Q, Zhang W, Wang G, He M, Liu M, Yang JK, Zhou HH. Acta Pharmacol Sin; 2012 Dec 15; 33(12):1563-70. PubMed ID: 23085740 [Abstract] [Full Text] [Related]
19. Effect of MDR1 C1236T polymorphism on cyclosporine pharmacokinetics: A systematic review and meta-analysis. Chen Z, Zhang L, Yang C, Jiang Z, Shen H, Gui G. Medicine (Baltimore); 2017 Nov 15; 96(47):e8700. PubMed ID: 29381954 [Abstract] [Full Text] [Related]
20. The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis. Liu YY, Li C, Cui Z, Fu X, Zhang S, Fan LL, Ma J, Li G. Gene; 2013 Dec 01; 531(2):476-88. PubMed ID: 24042126 [Abstract] [Full Text] [Related] Page: [Next] [New Search]